Sandoz' somatropin [recombinant human growth hormone; Omnitrope] has received marketing authorisation

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1463, 2004-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Use of Somatropin (Recombinant Growth Hormone) in Children of Short Stature

By Mehta A.   Hindmarsh P.C.  

Pediatric Drugs, Vol. 4, Iss. 1, 2002-01 ,pp. : 37-47

Adis International

Access to resources Recommend Favorite

Clinical applications of recombinant human growth hormone in adults

By Iglesias P.   Díez J.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 1, 1999-11 ,pp. : 97-107

Informa Healthcare

Access to resources Recommend Favorite

Supercritical Fluids Processing of Recombinant Human Growth Hormone

By Velaga Sitaram   Carlfors Johan  

Drug Development and Industrial Pharmacy, Vol. 31, Iss. 2, 2005-02 ,pp. : 135-149

Informa Healthcare

Access to resources Recommend Favorite

Health Canada has announced the withdrawal of marketing authorisation for Prexige [lumiracoxib]

By  

Reactions Weekly, Vol. 1, Iss. 1173, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Refusal of the marketing authorisation for Sumatriptan Galpharm has been confirmed by the EMA's CHMP.

By  

Reactions Weekly, Vol. 1, Iss. 1380, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite